Medexus Pharmaceuticals Inc.
MEDXF
$2.24
-$0.031-1.37%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -4.18% | -5.34% | -12.15% | -6.71% | 4.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -4.18% | -5.34% | -12.15% | -6.71% | 4.59% |
| Cost of Revenue | -6.59% | -5.70% | -10.18% | -0.96% | 13.36% |
| Gross Profit | -2.40% | -5.09% | -13.53% | -10.53% | -1.06% |
| SG&A Expenses | -3.76% | -9.84% | -12.70% | -9.80% | -7.01% |
| Depreciation & Amortization | 23.63% | 5.94% | -0.47% | -3.59% | -4.52% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.85% | -8.19% | -12.23% | -6.61% | 0.66% |
| Operating Income | -6.77% | 17.57% | -11.52% | -7.47% | 50.63% |
| Income Before Tax | 1,258.49% | 465.71% | 246.00% | 143.07% | 102.10% |
| Income Tax Expenses | -352.19% | 94.48% | 86.86% | 100.51% | 105.11% |
| Earnings from Continuing Operations | 1,150.00% | -39.42% | -53.23% | -66.61% | -117.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,150.00% | -39.42% | -53.23% | -66.61% | -117.53% |
| EBIT | -6.77% | 17.57% | -11.52% | -7.47% | 50.63% |
| EBITDA | 3.11% | 14.12% | -8.36% | -6.28% | 28.33% |
| EPS Basic | 882.79% | -51.61% | -62.17% | -78.32% | -119.71% |
| Normalized Basic EPS | 144.47% | 1,136.04% | 1,021.71% | 251.18% | 140.91% |
| EPS Diluted | 763.19% | -44.71% | -55.41% | -71.15% | -161.80% |
| Normalized Diluted EPS | 144.47% | 1,120.50% | 1,006.18% | 250.36% | 140.81% |
| Average Basic Shares Outstanding | 15.67% | 15.74% | 21.08% | 16.64% | 11.75% |
| Average Diluted Shares Outstanding | 15.67% | 12.83% | 17.88% | 13.54% | 8.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |